1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Addex Therapeutics – Product Pipeline Review – 2013

Addex Therapeutics – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 76 pages

Addex Therapeutics – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Addex Therapeutics - Product Pipeline Review - 2013” provides data on the Addex Therapeutics’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Addex Therapeutics’s corporate website, SEC filings, investor presentations and featured press releases, both from Addex Therapeutics and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Addex Therapeutics - Brief Addex Therapeutics overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Addex Therapeutics human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Addex Therapeutics with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Addex Therapeutics’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Addex Therapeutics’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Addex Therapeutics in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Addex Therapeutics’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Addex Therapeutics.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Addex Therapeutics and identify potential opportunities in those areas.

Table Of Contents

Addex Therapeutics - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Addex Therapeutics Snapshot 7
Addex Therapeutics Overview 7
Key Information 7
Key Facts 7
Addex Therapeutics - Research and Development Overview 8
Key Therapeutic Areas 8
Addex Therapeutics - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Addex Therapeutics - Pipeline Products Glance 13
Addex Therapeutics Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Addex Therapeutics - Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Addex Therapeutics - Drug Profiles 17
A2A-PAM 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
ADX-1 Program 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
ADX-2 Program 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
ADX-3 Program 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
ADX-63365 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
ADX-68692 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
ADX-71441 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
ADX-71743 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
ADX-71943 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
dipraglurant 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
FSHR/LHR NAM 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
GABABR PAM 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
GLP-1R PAM 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
IL1R1-NAM 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
mGluR2-NAM 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
mGluR4-PAM 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
mGluR7-NAM 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
TNFR1 NAM 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
TRKB PAM 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Addex Therapeutics - Pipeline Analysis 37
Addex Therapeutics - Pipeline Products by Therapeutic Class 37
Addex Therapeutics - Pipeline Products by Route of Administration 38
Addex Therapeutics - Pipeline Products By Mechanism of Action 39
Addex Therapeutics - Recent Pipeline Updates 41
Addex Therapeutics - Dormant Projects 46
Addex Therapeutics - Discontinued Pipeline Products 47
Discontinued Pipeline Product Profiles 47
ADX-10059 47
ADX-10061 47
Adenosine A3 Antagonist Program 47
Addex Therapeutics - Company Statement 48
Addex Therapeutics - Locations And Subsidiaries 49
Head Office 49
Other Locations and Subsidiaries 49
Addex Therapeutics, Recent Developments 50
Addex Therapeutics- Press Release 50
Mar 21, 2013: Addex Therapeutics Announces Presentation On Dipraglurant Phase IIa Study Results At 2013 Annual Meeting Of American Academy Of Neurology 50
Mar 19, 2013: Michael J. Fox Foundation Awards $1m Grant To Addex Therapeutics For Further Development Of Dipraglurant For Treatment Of Parkinson's Disease Levodopa-induced Dyskinesia 51
Jan 29, 2013: Addex Therapeutics's Dipraglurant Reduces Motor Abnormalities In Preclinical Model Of Dystonia 52
Jan 22, 2013: Addex Receives Broad US Composition Of Matter Patent For ADX71441 52
Jan 07, 2013: Addex Therapeutics Announces Positive Data With ADX71441 In Pre-Clinical Transgenic Model Of Charcot-Marie-Tooth 1A Disease 53
Sep 08, 2010: Addex Awarded Michael J. Fox Foundation Grant For ADX48621 To Treat Levodopa-Induced Dyskinesia In Parkinson's 54
Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer's Disease Model 55
Jul 13, 2010: Addex's ADX71943 Demonstrates Efficacy In Osteoarthritis Pain Model 55
Jun 15, 2010: Addex's ADX48621 Effective In Preclinical Parkinson's Disease Studies 56
Feb 08, 2010: Addex Demonstrates Analgesic Effects Of ADX71943 In Three Preclinical Models 57
Financial Deals Landscape 58
Addex Therapeutics, Deals Summary 58
Addex Therapeutics, Pharmaceuticals and Healthcare, Deal Details 59
Partnerships 59
Addex Therapeutics And Viva Biotech Partner To Advance Allosteric Modulators Targeting Adenosine 2A Receptor 59
Licensing Agreements 61
Addex Pharma Extends Collaboration Agreement With Merck and Co. 61
Addex Pharma Enters Into A License Agreement With Merck and Co 63
Addex Pharma Enters Into Collaboration And Licensing Agreement With Merck and Co 65
Equity Offering 67
Addex Therapeutics Completes Private Placement Of Shares For $11 Million 67
Addex Pharma Completes Private Placement Of $5.93 Million 69
Addex Pharma Completes IPO Of $111.3 Million 71
Debt Offering 73
Addex Pharma Completes Private Placement Of Mandatory Convertible Notes For $13.8 Million 73
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76



List of Tables

Addex Therapeutics, Key Information 7
Addex Therapeutics, Key Facts 7
Addex Therapeutics - Pipeline by Indication, 2013 9
Addex Therapeutics - Pipeline by Stage of Development, 2013 11
Addex Therapeutics - Monotherapy Products in Pipeline, 2013 12
Addex Therapeutics - Phase II, 2013 13
Addex Therapeutics - Phase I, 2013 14
Addex Therapeutics - Pre-Clinical, 2013 15
Addex Therapeutics - Discovery, 2013 16
Addex Therapeutics - Pipeline By Therapeutic Class, 2013 37
Addex Therapeutics - Pipeline By Route of Administration, 2013 38
Addex Therapeutics - Pipeline Products By Mechanism of Action, 2013 40
Addex Therapeutics - Recent Pipeline Updates, 2013 41
Addex Therapeutics - Dormant Developmental Projects,2013 46
Addex Therapeutics - Discontinued Pipeline Products, 2013 47
Addex Therapeutics, Subsidiaries 49
Addex Therapeutics, Deals Summary 58
Addex Therapeutics And Viva Biotech Partner To Advance Allosteric Modulators Targeting Adenosine 2A Receptor 59
Addex Pharma Extends Collaboration Agreement With Merck and Co. 61
Addex Pharma Enters Into A License Agreement With Merck and Co 63
Addex Pharma Enters Into Collaboration And Licensing Agreement With Merck and Co 65
Addex Therapeutics Completes Private Placement Of Shares For $11 Million 67
Addex Pharma Completes Private Placement Of $5.93 Million 69
Addex Pharma Completes IPO Of $111.3 Million 71
Addex Pharma Completes Private Placement Of Mandatory Convertible Notes For $13.8 Million 73



List of Figures

Addex Therapeutics - Pipeline by Indication, 2013 9
Addex Therapeutics - Pipeline by Stage of Development, 2013 11
Addex Therapeutics - Monotherapy Products in Pipeline, 2013 12
Addex Therapeutics - Pipeline By Therapeutic Class, 2013 37
Addex Therapeutics - Pipeline By Route of Administration, 2013 38
Addex Therapeutics - Pipeline Products By Mechanism of Action, 2013 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.